Novartis buys gene therapy firm Arctos Medical in vision loss treatment push – Reuters

Novartis' logo is seen at the cell and gene therapy factory of the Swiss drugmaker in Stein, Switzerland, November 28, 2019. REUTERS/Arnd Wiegmann/File Photo
ZURICH, Sept 21 (Reuters) – Swiss drugmaker Novartis (NOVN.S) said on Tuesday it has bought gene therapy specialist Arctos Medical for an undisclosed amount, aiming to boost its efforts to find treatments for severe vision loss.
Arctos's technology is a potential way to treat inherited retinal dystrophies (IRDs) and other diseases that involve photoreceptor loss, such as age-related macular degeneration (AMD).
Existing gene therapy treatments aim to correct a specific gene, so only a small number of patients can benefit, Novartis said. The Arctos technology is not limited to a specific gene, and can potentially address many forms of IRDs, it said.
IRDs affect more than 2 million people globally and often result in complete blindness. AMD, meanwhile, affects an estimated 170 million people globally, Novartis said.
The acquisition underscores its commitment to using optogenetics-based therapies to restore vision to patients with advanced blindness, the company said.
"Optogenetics is emerging as a promising therapeutic approach that might restore sight to patients who are legally blind," Jay Bradner, president of the Novartis Institutes for BioMedical Research, said in a statement.
Our Standards: The Thomson Reuters Trust Principles.
Subscribe for our daily curated newsletter to receive the latest exclusive Reuters coverage delivered to your inbox.
Abortion providers in Texas on Thursday asked the U.S. Supreme Court to intervene on an urgent basis in their challenge to a state law imposing a near-total ban on abortion.
Reuters, the news and media division of Thomson Reuters, is the world’s largest multimedia news provider, reaching billions of people worldwide every day. Reuters provides business, financial, national and international news to professionals via desktop terminals, the world's media organizations, industry events and directly to consumers.
Build the strongest argument relying on authoritative content, attorney-editor expertise, and industry defining technology.
The most comprehensive solution to manage all your complex and ever-expanding tax and compliance needs.
The industry leader for online information for tax, accounting and finance professionals.
Information, analytics and exclusive news on financial markets – delivered in an intuitive desktop and mobile interface.
Access to real-time, reference, and non-real time data in the cloud to power your enterprise.
Screen for heightened risk individual and entities globally to help uncover hidden risks in business relationships and human networks.
All quotes delayed a minimum of 15 minutes. See here for a complete list of exchanges and delays.
© 2021 Reuters. All rights reserved

source